查詢結果分析
相關文獻
- Thymalfasin用於治療C型肝炎
- Rational Approach to the Clinical Protocol Design for Drug Combinations: A Review
- Probable Reinfection with Hepatitis C Virus in a Chronic Hepatitis C Patient with a Sustained Response to Combination Therapy
- Successful Treatment of Three Intracranial Mycotic Aneurysms with a Combination of Antibiotics, Endovascular, and Surgical Therapies: A Case Report
- 小柴胡加減方對慢性C型病毒性肝炎之治療效果
- Gamma Knife Radiosurgery for Recurrent Nasopharyngeal Cancer
- 中藥治療白血球低下症:一病例報告
- In Vitro Activities of Antibiotic Combinations Against Clinical Isolates of Pseudomonas Aeruginosa
- Varenicline合併尼古丁替代療法比Varenicline單一藥物有效
- 抗生素老藥新用之趨勢
頁籤選單縮合
題名 | Thymalfasin用於治療C型肝炎=Thymalfasin for Treating Hepatitis C |
---|---|
作者姓名(中文) | 白雅君; 賴建名; | 書刊名 | 藥學雜誌 |
卷期 | 28:3=112 2012.09[民101.09] |
頁次 | 頁51-55 |
分類號 | 418.29 |
關鍵詞 | C型病毒性肝炎; 合併療法; Thymosin α1; Thymalfasin; |
語文 | 中文(Chinese) |
中文摘要 | 疾病管制局依傳染病防治法將C型病毒性肝炎歸為第三類法定傳染病,目前核准治療C型肝炎的藥品有 interferon 與 ribavirin,但常因顯著的副作用必須調整劑量或甚至停藥,進而影響藥品療程。Thymalfasin 為一種免疫調節劑,主要治療因免疫低下引起的相關疾病,此藥治療於C型肝炎目前在歐洲與美國皆屬臨床試驗 phase III。完成加入 thymalfasin 的合併療法患者中,發現此合併療法能清除部分對之前單一或合併療法無效患者體內的病毒。目前有些國家已核准上市使用,美國與歐洲仍持續在進行臨床試驗,希望藉由證據力更高的研究支持這項合併療法達到C型肝炎的治療目標。 |
英文摘要 | Hepatitis C accounts for a sizable proportion of cases of chronic liver disease, liver disease deaths, and cases of hepatocellular carcinoma and represents the most common indication for liver transplantation. The majority of patients who are infected with genotype 1 HCV and have high viral loads do not achieve a sustained response. Thymalfasin (Zadaxin, TA-1, thymosin alpha 1) is in phase III trials for the treatment of hepatitis C virus (HCV) in patients who are non-responders to prior therapy. Thymalfasin showed efficacy in the treatment of chronic HCV infection and demonstrated a consistent pattern of tolerability and safety in clinical trials. Use of immunomodulators such as thymalfasin may have an adjuvant role in promoting responses for both current and future hepatitis C treatment modalities. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。